AAAbena Appiah-Kubi

Abena Appiah-Kubi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Abena Appiah-Kubi has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Real-world safety profile of twice a day deferiprone in patients with thalassemia, sickle cell disease, or other anemias

    by Sujit Sheth, Ashutosh Lal, Abena Appiah-Kubi, Scott A. Peslak, Noemi Toiber Temin, Mengru Amanda Chen, Thomas D Coates

    Iron overload is a significant cause of transfusion-related morbidity and mortality. Deferiprone (DFP) is an established oral iron chelator approved for the treatment of transfusional iron overload in patients with thalassemia, sickle cell disease (SCD), or other anemias. Initially approved as a three times-a-day (TID) formulation, a twice-a-day (BID) formulation was developed to improve patient adherence. Here, we assess the safety of DFP BID in patients with thalassemia, SCD, or other anemias in real-world clinical practice in the United States. Data for patients referred for DFP BID between July 1, 2020 to August 31, 2023 were obtained from the Ferriprox® Total Care Registry. The frequency of adverse events (AEs), serious AEs (SAEs), AEs of special interest and fatal outcomes was assessed. Of the 425 patients referred to the registry, 348 received ≥one DFP shipment and had a primary diagnosis of thalassemia syndromes (N=129), SCD (N=189), or other anemias (N=30) (safety analysis group). Mean (SD) DFP exposure was 343.0 (281.9) days. In total, 1021 AEs and 369 SAEs were reported. As seen with the TID formulation, the most common adverse events with DFP BID were predominantly gastrointestinal or related to underlying disease. Cases of neutropenia and agranulocytosis were rare, reported in 1.7% and 0.6% of patients, respectively and all recovered. None of the 26 fatal outcomes reported were assessed as related to DFP treatment. DFP BID was well-tolerated in real-world clinical practice, and the safety profile was consistent with DFP TID. No new safety concerns were observed.

  • Open Access

    Hydroxyurea pharmacokinetics, it is a small world after all

    by Christina Caruso, Abena Appiah-Kubi


  • Open Access

    The Community Health Workers and Mobile Health for Emerging Adults Transitioning Sickle Cell Disease Care (COMETS) Trial: Protocol for a Randomized Controlled Trial

    by Tanisha D Belton, Caren M Steinway, Olivia Teng, Justine Shults, Lamia P Barakat, Banu Aygun, Abena Appiah-Kubi, Lori E Crosby, Omar Niss, Biree Andemariam, et al.

    Background: Transitioning from pediatric to adult sickle cell disease (SCD) care is challenging for emerging adults (aged 17-25 years). This period is marked by a 7-fold increase in mortality rates and has the highest rates of hospitalizations, emergency room visits, and hospital readmissions compared with children living with SCD. These challenges are exacerbated by fragmented care coordination, difficulty navigating adult health care systems, and increased self-management responsibilities. Objective: This study aims to compare the effectiveness of 2 interventions designed to support emerging adults living with SCD during this transition: a mobile health (mHealth) app and community health worker (CHW) support to standard care. Methods: The Community Health Workers and Mobile Health for Emerging Adults Transitioning Sickle Cell Disease Care (COMETS) trial is an ongoing multicenter, 3-arm, open-label randomized controlled trial; 375 emerging adults (aged 17-25 years) are being enrolled and randomized 1:1:1 to (1) a 6-month CHW intervention focused on self-management skills, symptom tracking, care coordination, and transition planning; (2) a 6-month mHealth self-management program (enhanced iManage application) with tailored SMS text messaging (THRIVE [Texting Health-Related Resources to Inform, Motivate, and Engage] 2.0); or (3) enhanced usual care (control). Participants are followed for 18 months. The primary outcome is the change in self-reported health-related quality of life assessed using the PedsQL SCD module. Secondary outcomes include acute care use (hospitalizations and emergency department visits), patient activation, self-management behavior, and successful transfer to adult hematology care. Results: The institutional review board at Children’s Hospital of Philadelphia approved this study in June 2018. Recruitment began in January 2019 and ended in December 2022; we completed data collection in November 2024. We have enrolled a total of 405 participants. Conclusions: This trial addresses a critical gap in transition intervention research for young adults with SCD. It will provide evidence on the comparative effectiveness of 2 promising interventions (CHW and mHealth) and inform the development of scalable and sustainable transition support programs. Findings will have implications for improving health-related quality of life, reducing acute care use, and promoting successful transition to adult-centered SCD care for this vulnerable population. Trial Registration: ClinicalTrials.gov NCT03648710; https://clinicaltrials.gov/study/NCT03648710 International Registered Report Identifier (IRRID): DERR1-10.2196/69239


  • Open Access

    The Community Health Workers and Mobile Health for Emerging Adults Transitioning Sickle Cell Disease Care (COMETS) Trial: Protocol for a Randomized Controlled Trial (Preprint)

    by Tanisha D Belton, Caren M Steinway, Olivia Teng, Justine Shults, Lamia P Barakat, Banu Aygun, Abena Appiah-Kubi, Lori E Crosby, Omar Niss, Biree Andemariam, et al.

    BACKGROUND Transitioning from pediatric to adult sickle cell disease (SCD) care is challenging for emerging adults (aged 17-25 years). This period is marked by a 7-fold increase in mortality rates and has the highest rates of hospitalizations, emergency room visits, and hospital readmissions compared with children living with SCD. These challenges are exacerbated by fragmented care coordination, difficulty navigating adult health care systems, and increased self-management responsibilities. OBJECTIVE This study aims to compare the effectiveness of 2 interventions designed to support emerging adults living with SCD during this transition: a mobile health (mHealth) app and community health worker (CHW) support to standard care. METHODS The Community Health Workers and Mobile Health for Emerging Adults Transitioning Sickle Cell Disease Care (COMETS) trial is an ongoing multicenter, 3-arm, open-label randomized controlled trial; 375 emerging adults (aged 17-25 years) are being enrolled and randomized 1:1:1 to (1) a 6-month CHW intervention focused on self-management skills, symptom tracking, care coordination, and transition planning; (2) a 6-month mHealth self-management program (enhanced iManage application) with tailored SMS text messaging (THRIVE [Texting Health-Related Resources to Inform, Motivate, and Engage] 2.0); or (3) enhanced usual care (control). Participants are followed for 18 months. The primary outcome is the change in self-reported health-related quality of life assessed using the PedsQL SCD module. Secondary outcomes include acute care use (hospitalizations and emergency department visits), patient activation, self-management behavior, and successful transfer to adult hematology care. RESULTS The institutional review board at Children’s Hospital of Philadelphia approved this study in June 2018. Recruitment began in January 2019 and ended in December 2022; we completed data collection in November 2024. We have enrolled a total of 405 participants. CONCLUSIONS This trial addresses a critical gap in transition intervention research for young adults with SCD. It will provide evidence on the comparative effectiveness of 2 promising interventions (CHW and mHealth) and inform the development of scalable and sustainable transition support programs. Findings will have implications for improving health-related quality of life, reducing acute care use, and promoting successful transition to adult-centered SCD care for this vulnerable population. CLINICALTRIAL ClinicalTrials.gov NCT03648710; https://clinicaltrials.gov/study/NCT03648710 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/69239

  • Open Access

    Cardiopulmonary Complications of Sickle Cell Disease in Children

    by Maria Teresa Santiago, Lance Feld, Arushi Dhar, La Nyka Christian-Weekes, Abena Appiah-Kubi, Elizabeth Mitchell, Banu Aygun, Elizabeth K. Fiorino

    Sickle cell disease (SCD) is an autosomal recessive hemoglobinopathy leading to hemolysis, increased endothelial adhesion, inflammation, and vasculopathy. While most children with SCD have normal pulmonary function, lung capacity and expiratory flows are lower compared to age- and racially matched controls. Airway obstruction dominates in children, with restrictive ventilatory defects becoming more prevalent in adolescents and young adults. Decreased pulmonary function, physician-diagnosed asthma, airway hyperresponsiveness, wheezing, and sleep-disordered breathing are associated with more frequent episodes of acute chest syndrome and vaso-occlusive crisis. Chronic lung disease, thromboembolism, hypoxemia, and sleep-disordered breathing are associated with the development of pulmonary hypertension and ventricular dysfunction which carry significant morbidity and mortality risk in adults. Most treatments for cardiopulmonary complications of SCD are based on guidelines developed for the general population. Although most guidelines do not recommend routine screening of asymptomatic children, patients with cardiopulmonary symptoms should be monitored and treated by subspecialists in a multidisciplinary setting. Disease modifying treatments such as hydroxyurea are attenuating some of the cardiopulmonary complications in SCD. More studies need to be done to assess the effects of newer disease modifying treatments targeting hemolysis and decreasing endothelial adhesion.

  • Mental health assessment of youth with sickle cell disease and their primary caregivers during the COVID‐19 pandemic

    by Nancy S. Green, Deepa Manwani, Kim Smith‐Whitley, Banu Aygun, Abena Appiah‐Kubi, Arlene M. Smaldone

    Youth with sickle cell disease (SCD) and their caregivers are susceptible to stress and depression, perhaps exacerbated by pandemic‐associated health and economic concerns. Most of the 50 youth–caregiver dyads enrolled in the multisite trial, Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment (HABIT), took an online survey of self‐reported mental health symptoms and food insecurity during the 2020 COVID‐19 pandemic. Compared to largely pre‐pandemic results, prevalence of mental health symptoms in dyad members appeared to have shifted: fewer youth and more caregivers were affected during the pandemic; many of both groups lacked optimism. Pandemic/post‐pandemic screening of youth with SCD for mental health symptoms and food insecurity appears warranted.


  • Documented Viral Illness at the Time of Splenic Sequestration Does Not Affect the Odds of Recurrence in Children With Sickle Cell Disease

    by Omoyeni Clement, Joanna Fishbein, Abena Appiah-Kubi, Banu Aygun

    This retrospective study investigates the relationship between the presence of a documented viral infection in children with sickle cell disease during their first splenic sequestration crisis and their odds of recurrence. Forty-eight children were admitted to our hospital between 2008 and 2018 with a splenic sequestration crisis. Thirty-six had respiratory viral panels done on admission, 13 of whom were positive. Two additional children were diagnosed with parvovirus B19 infection by serology. The recurrence rate was 52% (17/33) for those deemed negative for viral illness compared with 33% (5/15) among those with a positive documented viral illness, which was not statistically different (P=0.35). HbSC genotype decreased, and reticulocytosis increased the odds of recurrence. Further research is needed to substantiate these findings.


  • Open Access

    Longitudinal analysis of cardiac abnormalities in pediatric patients with sickle cell anemia and effect of hydroxyurea therapy

    by Arushi Dhar, Tung Ming Leung, Abena Appiah-Kubi, Dorota Gruber, Banu Aygun, Olivia Serigano, Elizabeth Mitchell

    Cardiac abnormalities such as left ventricular hypertrophy, left ventricular dilation, and pulmonary hypertension in sickle cell anemia have been previously described. Hydroxyurea, a disease-modifying therapy for sickle cell anemia, has been used for several decades. Longitudinal assessment of echocardiographic abnormalities in children and young adults with sickle cell anemia receiving hydroxyurea therapy is lacking. The goal of this retrospective study was to determine the prevalence of echocardiographic abnormalities in children and young adults with sickle cell anemia and to examine the effects of hydroxyurea on reverse cardiac remodeling. We reviewed the records of patients with sickle cell anemia who underwent routine cardiac screening at Cohen Children’s Medical Center between 2010 and 2017, followed by retrospective longitudinal analysis of echocardiograms performed on patients receiving treatment with hydroxyurea. Data on a total of 100 patients with sickle cell anemia were analyzed; 60 (60%) were being treated with hydroxyurea. Twenty-five (41.6%) of the patients on hydroxyurea had been treated for 1 year. Serial echocardiograms of patients receiving hydroxyurea were then analyzed. Left ventricular dilation and hypertrophy improved significantly with hydroxyurea treatment. In addition, the left ventricular volume and mass correlated negatively with duration of treatment with hydroxyurea. Our study provides evidence that prolonged hydroxyurea therapy may lead to reverse cardiac remodeling. Future studies should attempt to follow up this patient cohort for a longer duration.


  • Open Access

    Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia

    by Emily R. Meier, Susan E. Creary, Matthew M. Heeney, Min Dong, Abena O. Appiah-Kubi, Stephen C. Nelson, Omar Niss, Connie Piccone, Maa-Ohui Quarmyne, Charles T. Quinn, et al.

    Background: Sickle cell disease (SCD) is a severe and devastating hematological disorder that affects over 100,000 persons in the USA and millions worldwide. Hydroxyurea is the primary disease-modifying therapy for the SCD, with proven benefits to reduce both short-term and long-term complications. Despite the well-described inter-patient variability in pharmacokinetics (PK), pharmacodynamics, and optimal dose, hydroxyurea is traditionally initiated at a weight-based dose with a subsequent conservative dose escalation strategy to avoid myelosuppression. Because the dose escalation process is time consuming and requires frequent laboratory checks, many providers default to a fixed dose, resulting in inadequate hydroxyurea exposure and suboptimal benefits for many patients. Results from a single-center trial of individualized, PK-guided dosing of hydroxyurea for children with SCD suggest that individualized dosing achieves the optimal dose more rapidly and provides superior clinical and laboratory benefits than traditional dosing strategies. However, it is not clear whether these results were due to individualized dosing, the young age that hydroxyurea treatment was initiated in the study, or both. The Hydroxyurea Optimization through Precision Study (HOPS) aims to validate the feasibility and benefits of this PK-guided dosing approach in a multi-center trial.Methods: HOPS is a randomized, multicenter trial comparing standard vs. PK-guided dosing for children with SCD as they initiate hydroxyurea therapy. Participants (ages 6 months through 21 years), recruited from 11 pediatric sickle cell centers across the USA, are randomized to receive hydroxyurea either using a starting dose of 20 mg/kg/day (Standard Arm) or a PK-guided dose (Alternative Arm). PK data will be collected using a novel sparse microsampling approach requiring only 10 μL of blood collected at 3 time-points over 3 h. A protocol-guided strategy more aggressive protocols is then used to guide dose escalations and reductions in both arms following initiation of hydroxyurea. The primary endpoint is the mean %HbF after 6 months of hydroxyurea.Discussion: HOPS will answer important questions about the clinical feasibility, benefits, and safety of PK-guided dosing of hydroxyurea for children with SCD with potential to change the treatment paradigm from a standard weight-based approach to one that safely and effectively optimize the laboratory and clinical response.Trial registration: ClinicalTrials.govNCT03789591. Registered on 28 December 2018.


  • Varying presentations and favourable outcomes of COVID‐19 infection in children and young adults with sickle cell disease: an additional case series with comparisons to published cases

    by Abena Appiah‐Kubi, Suchitra Acharya, Carolyn Fein Levy, Adrianna Vlachos, Gholamabbas Ostovar, Kristina Murphy, Antonella Farrell, Donna Brower, Jeffrey M. Lipton, Lawrence Wolfe, et al.

    Patients with sickle cell disease (SCD) are theoretically at greater risk for serious illness from COVID 19 due to the underlying pathophysiology of chronic inflammation with an increased risk of thrombosis, especially at the time of a vaso‐occlusive event (1). Individuals living with SCD are also considered to be immunocompromised due to autoinfarction of their spleen or surgical splenectomy, often as a result of red cell splenic sequestration (2). In addition, patients with SCD often have comorbidities and secondary organ dysfunction that can put them at risk of significant morbidity and or mortality from the severe acute respiratory coronavirus 2 (SARS‐CoV‐2), and its subsequent disease COVID‐19.